🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Lepu Biopharma clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Lepu Biopharma as lead sponsor. Synced 26 Sep 2026
10Current trials
7Recruiting now
10Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Lepu Biopharma is the lead sponsor of 10 current clinical trials in our China register. 7 are recruiting patients now. The most common phase is Phase 1/2. The drugs named most often in its trials are Becotatug Vedotin, Pucotenlimab and Bevacizumab. The most-studied condition is Advanced Solid Tumors.

ClinicalTrials.gov trials by status

  • Recruiting770%
  • Not yet open220%
  • Active, closed110%

Trials by phase

  • Phase 1/2440%
  • Phase 3330%
  • Phase 2330%
01

Clinical trials sponsored by Lepu Biopharma

10 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN
NCT05751512 · ClinicalTrials.gov ↗ · Squamous Cell Carcinoma of the Head and Neck
Phase 3 Recruiting 2023-04 China
Pucotenlimab Plus Becotatug Vedotin in Perioperative Treatment of Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma
NCT07586124 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma
Phase 2 Recruiting 2026-07 China
A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors
NCT05688605 · ClinicalTrials.gov ↗ · Advanced Solid Tumors
Phase 1/2 Recruiting 2022-06 China
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
NCT07283835 · ClinicalTrials.gov ↗ · Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer
Phase 2 Recruiting 2025-12 China
MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
NCT07479485 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma
Phase 1/2 Recruiting 2026-04 China
A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
NCT06976190 · ClinicalTrials.gov ↗ · Recurrent or Metastatic Nasopharyngeal Carcinoma
Phase 3 Recruiting 2025-05 China
A Study of MRG006A in the Treatment of Patients With Advanced Solid Tumors
NCT07093970 · ClinicalTrials.gov ↗ · Advanced Solid Tumors
Drug: MRG006A
Phase 1/2 Recruiting 2024-07 China
A Study of MRG007 Combination Therapy for Advanced Colorectal Cancer
NCT07737600 · ClinicalTrials.gov ↗ · Advanced Colorectal Cancer
Phase 1/2 Not yet open 2026-08 China
A Study Comparing MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Cancer
NCT07138846 · ClinicalTrials.gov ↗ · Advanced Pancreatic Cancer
Phase 3 Not yet open 2027-01 China
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma
NCT05126719 · ClinicalTrials.gov ↗ · Recurrent or Metastatic Nasopharyngeal Carcinoma
Phase 2 Active, closed 2023-04 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Lepu Biopharma trials

10 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Lepu Biopharma trials

9 conditions
Advanced Solid Tumors2Recurrent or Metastatic Nasopharyngeal Carcinoma2Squamous Cell Carcinoma of the Head and Neck1Head and Neck Squamous Cell Carcinoma1Advanced Colorectal Cancer1Non Muscle Invasive Bladder Cancer1High-grade Ta/ T1 Papillary Disease Bladder Cancer1Hepatocellular Carcinoma1Advanced Pancreatic Cancer1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China107

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Advanced Solid Tumors

SponsorTrials
Sichuan Kelun-Biotech Biopharmaceutical9
Jiangsu HengRui Medicine7
Suzhou Suncadia Biopharmaceuticals7
Shanghai Hengrui Pharmaceutical6
Bristol-Myers Squibb5
MediLink Therapeutics (Suzhou)5
Hangzhou Zhongmei Huadong Pharmaceutical5
Hansoh BioMedical R&D Company4
Bayer3
Vividion Therapeutics3

Sponsors with the most current trials registered for this condition.

06

Questions about Lepu Biopharma trials

How many clinical trials does Lepu Biopharma sponsor?

Lepu Biopharma is the lead sponsor of 10 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Lepu Biopharma trials recruiting?

Yes. 7 of its 10 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Lepu Biopharma testing?

Its current trials name 10 drugs and biologicals as interventions. The most frequent are Becotatug Vedotin (4), Pucotenlimab (4), Bevacizumab (2), Capecitabine (2) and MRG006A (2). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.